About Vernalis

Peter Fellner was appointed as Chairman in January 2003 and as executive Chairman in April 2003. He was Chairman of Celltech Group plc until its acquisition in mid-2004, having previously served as its Chief Executive Officer from 1990 to 2003. Before joining Celltech he was Chief Executive of Roche UK from 1986 to 1990. Dr Fellner is also Chairman of Astex Therapeutics Ltd and Consort Medical plc and is a director of UCB SA, QinetiQ Group plc and Evotec AG.  He also recently served as Chairman of Acambis plc from 2006 until its acquisition in September 2008 and as Chairman of Premier Research Group plc, from 2007 until its sale to private equity in mid 2008.

Ian Garland was appointed as Chief Executive Officer in December 2008. From May 2007 until September 2008, Ian was CEO of Acambis plc.  During this period he oversaw a series of important advances culminating in the company's acquisition by Sanofi-Aventis in September 2008 for £280m. From 2004 to 2007, Ian served as CFO of Arrow Therapeutics Ltd., a privately-held company engaged in the discovery and development of new anti-viral agents until its acquisition by AstraZeneca plc for US$150m in February 2007. Prior to this Ian was President and Chief Operating Officer of Celltech Pharmaceuticals Inc., with a turnover of around US$300 million which encompassed the US operations of Celltech Group plc. From 1988 to 1995 Ian worked at KPMG, specialising in the pharmaceutical sector, following qualification as a Chartered Accountant.

David Mackney was appointed as Chief Financial Officer in February 2009. From February 2008 until January 2009, David was Interim CFO at Acambis plc, working to successfully secure the US biodefence contract, the secondary financing and the acquisition of Acambis by Sanofi-Aventis in September 2008. Prior to Acambis he was CFO for a private equity-backed technology company. From January 2002 to May 2005, David served as Group Financial Controller at Shire plc, and from September 1996 to December 2001, he worked as a senior manager in audit and then in transaction services at Arthur Andersen. David is a Chartered Accountant.

George Kennedy was appointed as Deputy Chairman and Senior Independent Director on 1 September 2003. He was non-executive Chairman of Vernalis Group plc from May 2000. He was previously with Smiths Industries PLC from 1973 to 2000, where he was appointed to the board in 1983, becoming executive director and Chairman of the medical division. His other current appointments are Chairman of Eschmann Holdings Limited, a manufacturer of medical equipment; Chairman of E2V Technologies plc and non-executive director of Consort Medical Plc. His previous appointments include non-executive Chairman of Carclo PLC; Chairman of the Inprint Group, a privately-held specialist printing company and from August 2000 to December 2003 he was Chairman of the Trade Advisory Group for Africa and the Middle East and non-executive director of Isotron PLC. He was awarded a CBE in 1997 for services to the healthcare industry and exports.

Carol Ferguson was appointed as a non-executive director on 1 September 2003 having joined the Board of Vernalis Group plc as a non-executive director in May 2002. She is a former partner and lead oil analyst at stockbrokers Wood Mackenzie and was Finance Director of a textiles company. She is currently non-executive director of a number of companies including BlackRock Greater Europe Investment Trust, Monks Investment Trust, Standard Life Smaller Companies Investment Trust plc, Gartmore Smaller Companies Investment Trust, the Chartered Accountants Compensation Scheme, Ardana plc and Invesco Asia Investment Trust plc. She is also Chairman of the Association of Investment Companies Limited.  She is a graduate of St Andrews University and a member of the Institute of Chartered Accountants of Scotland.

Peter Read was appointed as a non-executive director on 1 September 2003. He joined the Board of Vernalis Group plc as a non-executive director in March 1998. He is a former Chairman of the Hoechst Group of Companies in the UK and a past President of the Association of the British Pharmaceutical Industry. Peter is a non-executive director of SSL International plc.  Peter's previous board appointments include Innogenetics Group and the South East of England Development Agency. He is a Fellow of the Royal College of Physicians and of the Faculty of Pharmaceutical Medicine. In January 2000 he was awarded a CBE for services to the pharmaceutical industry.

Allan Baxter was appointed as a non-executive director on 19 May 2004. He is Senior Vice President of Medicines Development at GlaxoSmithKline with responsibility for GlaxoSmithKline’s worldwide late-stage development effort, responsible for life cycle management of Marketed Medicines from the time they have demonstrated clinical proof-of-concept.

Ian Clark was appointed as a non-executive director on 1st January 2007.  He currently serves as Executive Vice President, Commercial Operations at Genentech and is responsible for leading their commercial organisation, including the Sales, Marketing, Managed Care, Customer Operations and Commercial Support functions. Prior to joining Genentech in 2003, he served as president of Novartis Canada, overseeing all of the company's country operations.  Before assuming his post in Canada, he served as Chief Operating Officer for Novartis in the UK.  Prior to joining Novartis in 1999, Ian worked in Vice Presidential roles in sales and marketing for Sanofi-Aventis and Ivax in the UK and Eastern Europe.  He received a Bachelor of Science degree in Biological Sciences from Southampton University.